# Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

> **NCT07350577** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AltruBio Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **BIOLOGICAL:** ALTB-268
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07350577
- **Lead sponsor:** AltruBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-17
- **Primary completion:** 2026-09-26
- **Final completion:** 2026-09-28
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07350577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07350577, "Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07350577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*